IMPACT OF UGT1A9 AND CYP2B6 POLYMORPHISM ON PHARMACOKINETICS OF PROPOFOL IN KOREAN PATIENTS.

被引：0
|
作者：
Kim, M. [1 ]
Jin, S. [1 ]
Noh, G. [1 ,2 ]
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
[2] Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 91卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [31] VARIABILITY IN SERTRALINE PHARMACOKINETICS EXPLAINED BY CYP2C19 AND CYP2B6
    Ramsey, Laura B.
    Poweleit, Ethan A.
    Vaughn, Samuel
    Momper, Jeremiah
    Desta, Zeruesenay
    Strawn, Jeffrey Robert
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2024, 63 (10): : S194 - S194
  • [32] Haplotype structure and allele frequencies of CYP2B6 in a Korean population
    Cho, JY
    Lim, HS
    Chung, JY
    Yu, KS
    Kim, JR
    Shin, SG
    Jang, IJ
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (12) : 1341 - 1344
  • [33] Effect of CYB2B6 (c.516G>T), CYP2C9 (c.1075A>C) and UGT1A9 (c.98T>C) polymorphisms on propofol pharmacokinetics in patients submitted to colonoscopy: a cohort study
    Maricato Poma, Mara Aparecida
    Ribeiro Junior, Howard Lopes
    Costa, Eugenio Araujo
    Koscky Paier, Carlos Roberto
    Brasil, Lais Lacerda
    Lima, Luina Benevides
    Soares Nobre, Livia Maria
    Leite, Tayales Tavares
    Pereira Lima-Junior, Roberto Cesar
    Pinto Quidute, Ana Rosa
    Amaral de Moraes, Maria Elisabete
    de Moraes Filho, Manoel Odorico
    POSTGRADUATE MEDICAL JOURNAL, 2023, 99 (1170) : 286 - 295
  • [34] Evaluation of UGT protein interactions in human hepatocytes: Effect of siRNA down regulation of UGT1A9 and UGT2B7 on propofol glucuronidation in human hepatocytes
    Konopnicki, Camille M.
    Dickmann, Leslie J.
    Tracy, Jeffrey M.
    Tukey, Robert H.
    Wienkers, Larry C.
    Foti, Robert S.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2013, 535 (02) : 143 - 149
  • [35] Efavirenz and CYP2B6 polymorphism:: Implications for drug toxicity and resistance
    Nolan, D
    Phillips, E
    Mallal, S
    CLINICAL INFECTIOUS DISEASES, 2006, 42 (03) : 408 - 410
  • [36] Molecular simulation study of CYP2B6 polymorphism with and without psoralen
    Lu, Nan
    Meng, Fancui
    Xu, Weiren
    Tang, Lida
    Xu, Youjun
    MOLECULAR SIMULATION, 2018, 44 (17) : 1402 - 1410
  • [37] Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects
    Kim, K. A.
    Song, W. K.
    Park, J. Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (05) : 511 - 518
  • [38] Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients
    Nakajima, Miki
    Komagata, Sayaka
    Fujiki, Yuto
    Kanada, Yoshihiro
    Ebi, Hiromichi
    Itoh, Kuniaki
    Mukai, Hirofumi
    Yokoi, Tsuyoshi
    Minami, Hironobu
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (06): : 431 - 445
  • [39] Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism
    Martignoni, E
    Cosentino, M
    Ferrari, M
    Porta, G
    Mattarucchi, E
    Marino, F
    Lecchini, S
    Nappi, G
    NEUROLOGY, 2005, 65 (11) : 1820 - 1822
  • [40] In vitro glucuronidation of mycophenolic acid by human UGTs and the impact of known polymorphisms of UGT1A8, UGT1A9, and UGT2B7
    Bernard, O
    Guillemette, C
    DRUG METABOLISM REVIEWS, 2003, 35 : 53 - 53
12345